TLDR:
- In the third quarter of fiscal year 2026, Medtronic experiences an 8.7% revenue growth, led by the cardiac and diabetes sectors.
- The cardiac ablation division witnesses an 80% revenue growth, driven by PFA technology.
- The diabetes business grows by 8.3%, spurred by strong international demand.
- Medtronic’s Q3 operating profit reaches $1.464 billion, indicating solid margins.
- The company retains a strong growth outlook, supported by new market expansion.
Medtronic plc (MDT) has reported a solid performance in the third quarter of fiscal year 2026, exceeding expectations. The company generated $9.0 billion in revenue, a reported increase of 8.7% and a 6.0% increase on an organic basis. The revenue growth was driven by strong performances across key portfolios, especially in cardiac ablation and diabetes.
Cardiac Ablation Revenue Sees Robust Growth
Medtronic’s Cardiac Ablation Solutions business had remarkable growth in Q3. It increased by 80%, including a 137% jump in the U.S. The success was mainly driven by the strength of Medtronic’s pulsed field ablation (PFA) portfolio, which continues to make progress in treating cardiac arrhythmias.
The company achieved significant regulatory milestones. Medtronic obtained the CE Mark for its Sphere – 360
device, further strengthening its position in the cardiac ablation market. The U.S. pivotal trial for the device was also launched, suggesting potential long – term benefits for MDT’s growth in this sector.
Medtronic’s ability to accelerate innovation in cardiac care contributes to its strong market position. The combination of an expanding portfolio and increasing adoption of PFA technologies highlights the company’s leadership in this area.
Diabetes Revenue Rises on International Demand
Medtronic’s diabetes division also reported impressive results during the quarter. The business’s revenue grew by 8.3%, mainly driven by strong international market performance. This growth demonstrates the increasing global demand for Medtronic’s diabetes products, including its insulin pumps and continuous glucose monitoring systems.
Medtronic’s focus on expanding its presence in international markets has paid off. Its ability to provide tailored solutions for diverse regions is helping to drive growth. As Medtronic continues to innovate within its diabetes portfolio, the company remains a dominant force in the market.
With a strong pipeline of future products, Medtronic aims to maintain growth in its diabetes division. The global trend towards better diabetes management solutions presents significant opportunities for MDT.
Strong Financial Performance Reinforces Market Confidence
Medtronic’s financial results further strengthen its position in the sector. The Q3 GAAP operating profit reached $1.464 billion, with an operating margin of 16.2%. The non – GAAP operating profit was $2.177 billion, reflecting a margin of 24.1%, highlighting the company’s ability to generate strong profitability.
Medtronic continues to build confidence in its future, maintaining its FY26 organic revenue and EPS guidance. CEO Geoff Martha emphasized the company’s strategy of expanding into new markets and investing in high – growth opportunities, which is expected to drive sustained long – term growth. Medtronic’s strong portfolio and innovative pipeline offer a promising outlook for the coming quarters.
